Literature DB >> 11007109

5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer.

W A Brown1, K C Farmer, S A Skinner, C Malcontenti-Wilson, A Misajon, P E O'Brien.   

Abstract

The ability of 5-aminosalicylic acid and olsalazine to inhibit colonic aberrant crypts and tumors was investigated in 1,2-dimethylhydrazine-treated rats. The effect of these drugs on the rates of tumor apoptosis and proliferation was studied as potential mechanisms for their action. 5-Aminosalicylic acid reduced the number of aberrant crypt foci by over one third, while olsalazine had no effect on this parameter. However, both agents effectively reduced tumor number and load, increased the rate of tumor apoptosis, and reduced the rate of tumor cell proliferation. In conclusion, 5-aminosalicylic acid and olsalazine are both ultimately effective chemopreventive agents in this model; however, only 5-aminosalicylic acid inhibited the formation of aberrant crypt foci. The inhibitory effect of these agents in tumors is related to the inhibition of proliferation and the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007109     DOI: 10.1023/a:1005517112039

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  The colorectal tumor suppressor APC and its partners.

Authors:  J Samarut
Journal:  Jpn J Cancer Res       Date:  1997-08

2.  Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells.

Authors:  H Sheng; J Shao; E B Hooton; M Tsujii; R N DuBois; R D Beauchamp
Journal:  Cell Growth Differ       Date:  1997-04

3.  AOM-induced mouse colon tumors do not express full-length APC protein.

Authors:  T Maltzman; J Whittington; L Driggers; J Stephens; D Ahnen
Journal:  Carcinogenesis       Date:  1997-12       Impact factor: 4.944

4.  Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis.

Authors:  T A Chan; P J Morin; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

5.  Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors.

Authors:  M Takahashi; K Fukuda; T Sugimura; K Wakabayashi
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

6.  Bcl-2 interrupts the ceramide-mediated pathway of cell death.

Authors:  J Zhang; N Alter; J C Reed; C Borner; L M Obeid; Y A Hannun
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

7.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

Authors:  S Markowitz; J Wang; L Myeroff; R Parsons; L Sun; J Lutterbaugh; R S Fan; E Zborowska; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

8.  Role for ceramide in cell cycle arrest.

Authors:  S Jayadev; B Liu; A E Bielawska; J Y Lee; F Nazaire; L M Obeid; Y A Hannun
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157

9.  Selenium inhibition of 1,2-dimethylhydrazine-induced colon carcinogenesis.

Authors:  M M Jacobs
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

  9 in total
  12 in total

Review 1.  Molecular basis of the potential of mesalazine to prevent colorectal cancer.

Authors:  Carmine Stolfi; Roberto Pellegrini; Eleonora Franze; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

2.  Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.

Authors:  Manisha Bajpai; Darren N Seril; James Van Gurp; Xin Geng; Janet Alvarez; Carlos D Minacapelli; Steve Gorin; Koushik K Das; Elizabeth Poplin; Jerry Cheng; Peter S Amenta; Kiron M Das
Journal:  Dig Dis Sci       Date:  2018-11-26       Impact factor: 3.199

Review 3.  5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.

Authors:  Yang Cheng; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

4.  Synthesis and Characterization of 5-Aminosalicylic Acid Based Poly(anhydride-esters) by Solution Polymerization.

Authors:  Youngmi Kim; Kathryn E Uhrich
Journal:  J Polym Sci A Polym Chem       Date:  2010-12-15       Impact factor: 2.702

5.  Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.

Authors:  Joel H Rubenstein; Akbar K Waljee; Joanne M Jeter; Fernando S Velayos; Uri Ladabaum; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

Review 6.  Colitis-associated neoplasia: molecular basis and clinical translation.

Authors:  Sebastian Foersch; Markus F Neurath
Journal:  Cell Mol Life Sci       Date:  2014-05-15       Impact factor: 9.261

7.  Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids.

Authors:  Juan Suárez; Yanina Romero-Zerbo; Lucia Márquez; Patricia Rivera; Mar Iglesias; Francisco J Bermúdez-Silva; Montserrat Andreu; Fernando Rodríguez de Fonseca
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

8.  Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.

Authors:  Elizabeth Managlia; Rebecca B Katzman; Jeffrey B Brown; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

9.  The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ.

Authors:  Christel Rousseaux; Noura El-Jamal; Mathurin Fumery; Caroline Dubuquoy; Olivier Romano; Denis Chatelain; Audrey Langlois; Benjamin Bertin; David Buob; Jean Frederic Colombel; Antoine Cortot; Pierre Desreumaux; Laurent Dubuquoy
Journal:  Carcinogenesis       Date:  2013-07-10       Impact factor: 4.944

10.  Comparison of the effects of olsalazine and decitabine on the expression of CDH1 and uPA genes and cytotoxicity in MDA-MB-231 breast cancer cells.

Authors:  Misagh Mohammadi Asl; Javad Mohammadi Asl; Mojgan Naghitorabi
Journal:  Res Pharm Sci       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.